You listened and you LOVED this episode, which is exactly why this is THE NUMBER ONE EPISODE of TheOncoPT Podcast for 2025!
In case you missed it, the most important cancer rehab research since the PAL trial debuted at ASCO 2025.
Today on the podcast, I’m joined by Scott Capozza, PT, who recently attended and presented at ASCO 2025. Scott breaks down what ASCO is, how it compares to APTA CSM, and why oncology rehab professionals need to be paying attention.
We dive into some of the key themes from this year’s conference, including the game-changing findings from the CHALLENGE trial and the growing emphasis on structured exercise as a critical part of cancer care.
But more importantly, we talk about how OncoPTs are perfectly positioned to take this research and turn it into action.
It’s not just about being at the table. It’s about putting research into practice, starting now—because our patients can’t wait.
Listen now!
About the CHALLENGE Trial
This study followed nearly 900 patients with stage III or high-risk stage II colon cancer randomly assigned to a structured exercise program or to receive educational materials on physical activity & nutrition.
In short, the participants in the structured exercise program experienced a reduction in recurrence or new cancer risk, plus increased overall survival. These findings are comparable to or even better than some chemotherapy regimens. THIS IS HUGE NEWS, Y’ALL.
Read about the CHALLENGE Trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2502760
For more info about ASCO Annual Meeting
Visit https://www.asco.org/annual-meeting.
Want to watch the episode instead?
Watch this week’s episode of TheOncoPT Podcast on our YouTube channel!
About Scott Capozza, PT
Scott Capozza, PT, MSPT serves as the physical therapist for the multi-disciplinary Smilow Cancer Hospital Survivorship Clinic at Yale Cancer Center and is also Yale New Haven Hospital’s first dedicated outpatient physical therapist in oncology rehabilitation. Scott was among the first class of board-certified clinical specialists in oncologic physical therapy in the country, and serves as a CCE for the oncology specialization exam through the ABPTS. He previously served as the Membership Engagement and Leadership Development Chairperson for the American Physical Therapy Association’s Academy of Oncologic Physical Therapy, and currently is a member of the APTA national Media Corps. Scott is the adjunct professor in Oncology Physical Therapy for both Quinnipiac and Sacred Heart Universities in Connecticut. He is also the co-author of the chapter ‘Young Adult Survivors’ in the textbook Oncology Rehabilitation: A Comprehensive Guidebook for Clinicians, and he has presented on both the national and international level on the rehabilitation needs of Adolescents and Young Adults with cancer.
Read his 2024 patient perspective piece ‘Patient Is Otherwise Healthy.’
Follow Scott on Instagram.
Follow Scott on LinkedIn.
Contact Scott at scottcapozza@gmail.com
Transcript
Dr. Elise K. Cantu (00:00)
Hey, Onco PT and welcome to the number one episode of 2025. If you’ve missed it, over the month of December, we recap the top episodes of 2025 based on viewer or guess listener downloads technically. So that’s how we get the numbers. I go into my podcast player. I get all of the deets across the platforms and resoundingly.
This was the top episode of 2025 and for exceptionally good reason. Now to give you an idea of just what kind of a landmark episode we’re talking about, the content of this episode is the first research study, genuinely, that I have had multiple patients come to sessions with me wanting to talk about it. Like they heard about it in the news.
Maybe their oncology team was talking about it. But this, I think, illustrates just how groundbreaking, how monumental the content of this episode is. And of course, the guests who delivered on this, no surprise, is one of the most frequently asked about guests of the Onco PT podcast. And that would be Scott Capozza. You know him, you love him. If you don’t, you need to know him, you need to love him. He’ll be around CSM for sure.
This, I’ve named him lovingly, the fun uncle. He rejected Godfather of OncoPT So we’re going with the uncle, the founding uncle of OncoPT because the amount of work that Scott Capozza has done to advance cancer rehab into like the 2020s, truly. And from the aspect of,
This is how we really bring this into practice with our patients. Exceptional.
The, like, listen, the Onco PT podcast is absolutely a Scott Capoza fan podcast. It’s just our unofficial title here. And so when I was reviewing the stats for, you know, top five episodes, top episodes of 2025, this was honestly no surprise whatsoever. And the numbers, like I said, totally just, if there was any doubt whatsoever about like, oh, you know, the top episodes genuinely, like I have a list here.
And there were some that were really, really close in the stats. And I was like, oh, okay, okay. You know, like, that’ll be tough. This one absolutely like rose above the rest. And I, again, it really speaks to just how incredible this content is. So what the heck are we talking about here? So Scott Capozzo recently, this past year, actually spoke at and attended the ASCO conference that was at the end of springtime, beginning of summer.
So ASCO is the American Society for Clinical Oncology, something to that extent. So it’s the big oncology conference that happens every year. And at this conference, there was a major study that was published. Scott will get into the details, okay? I’m just giving you the overview so you know what you’re getting yourself into. There was a major study that was published that really looked at the outcomes of when a person does exercise
we are seeing direct effects beneficially on their overall survival. You and I know this, right? This comes as no surprise if you have been in cancer rehab for longer than a week. We know the benefits of exercise. We know the benefits of physical activity. We know the benefits of rehab and helping all of these things. But this
unquestionably and on an extremely large scale, right? This wasn’t just an N of 20. This was exceptionally large study, just very definitive results that I think is going to be a major
I don’t want to say turning point. I think this is momentum that we have to capitalize on. And I really get into this with Scott at the end of the episode. So I’ll also save that for you here. But I just want to kind of lead with this and then I’m going to let Scott take it away. We have a responsibility as cancer rehab professionals, as on-co-PTs, if you are listening to this podcast right now, of taking the awareness
the excitement and the momentum that came out of ASCO around exercise and the benefits that we see in our cancer survivors who participate. And we need to run with this. I’m saying we need to, if there is a way to both sprint and marathon at the same time, we have to do it because we need to quickly move forward with this, working to educate our communities about this, working to implement this in our own practice.
but we also need to make sure that that energy doesn’t end at the metaphorical 5K here, okay? We need to make sure that we are carrying this forward, continuing to use this, to use this to advocate for our patients, with our patients, for the inclusion of exercise, for the inclusion of cancer rehab, to help with this, to really ensure that all patients are able to access this, quote, magic pill that we talk about, you know, exercise.
really can be in this case of oncology to really help with a lot of the traditional treatments that we are still using and going to continue using with our patients. This is our moment and I think it is extremely fitting that this is the top episode of 2025 because of truly how landmark, monumental, earth-shattering, universe-shaking, whatever you want to use to describe it, this is a
enormous moment and kind of a crossroads of cancer rehab. And we can either choose to run with this sprint and marathon as I just talked about, or we can let this go. maybe that’s we let it pass us by. We let other professions kind of take ownership of this and kind of say, okay, cool. And just kind of let it happen. I’m not in that second camp. am
squarely firmly in this first camp. And if you’re listening to this podcast, that means that you are too. Now in no way am I trying to elevate physical therapy as like the end all be all for all of this. It takes all of us. It takes all of us as a team, as a field working together. But we have to step up and we have to take ownership of this in order to make this a reality for our patients. If we are going to avoid the disastrous 17 year wait that it takes from research to
go from being published to actually into practice as a standard of care, we have to do more. We have to be active in this. We have to be intentional with this. And that means that we have to take steps. We have to do the thing. So anyways, I’m so thrilled to bring you once again my interview with Scott Capoza and his recap of the ASCO conference and the incredible ⁓ literature and research that was published and presented at that conference. And I cannot wait for you to enjoy that episode again.
So listen up, you’re going to love it. And with that, because I’m not going to see you at the end of this episode, happy new year. I cannot wait to see you in the next one. We’ve got a ton of amazing stuff coming your way. You’re going to have to wait, but here is the number one episode of 2025 on the Onco PT podcast.
@TheOncoPT – Elise (08:09)
Hey, Onco PT and welcome back to this episode of the Onco PT podcast. As part of our conference course debrief series that we’re doing here at the Onco PT podcast, this podcast episode is going to blow your mind. If you did not see any of the updates that have come out of the ASCO 2025 conference this summer, you are going to lose your mind with the stuff that we are talking about today. Now, before we get into what that is,
I need to welcome our guest for today, Scott Capoza. You’ve been on the podcast a few times. It was time to have you back. Welcome back to the Onco PT podcast.
Scott Capozza (08:48)
It’s always great to chat with you.
@TheOncoPT – Elise (08:51)
Would you mind introducing yourself to the audience who maybe hasn’t met you yet?
Scott Capozza (08:57)
So again, I’m Scott Capoza. I’m a board certified clinical specialist in oncologic physical therapy. I work in outpatient oncology up in Connecticut. I’m pretty fortunate that not only do I work in traditional outpatient oncology settings, but I’m also integrated into a multidisciplinary cancer survivorship clinic, as well as a now more recently a multidisciplinary
@TheOncoPT – Elise (09:19)
Mm-hmm.
Scott Capozza (09:25)
GI surgical clinic, which is more of the more the prehab side of things. So I really feel, yeah, I’m really just really fortunate that I feel like I can see patients throughout the continuum of care, prehab, active treatment, survivorship. So that’s that’s who I am.
@TheOncoPT – Elise (09:28)
Ooh, yeah.
Very cool.
my gosh. Okay. So we’re talking today about the recent ASCO conference and you were there as a presenter and this is a conference that maybe some people have heard about, but maybe they haven’t. So can we really quick establish what is ASCO and therefore what is the ASCO conference?
Scott Capozza (10:05)
So ASCO stands for the American Society of Clinical Oncology. And so just like we have APTA, which is our national governing body for us as physical therapists, the oncologists have their national governing body, ⁓ and that’s ASCO. And just like we have CSM every year, they have a large annual meeting where
@TheOncoPT – Elise (10:15)
Mm-hmm.
Scott Capozza (10:32)
This year they had 44,000 people.
@TheOncoPT – Elise (10:35)
Holy cow.
Scott Capozza (10:37)
in attendance. I can’t remember what the number was from Houston this year, maybe 15 or 16,000. So, that almost three times as many people, all packed into the McCormick Center, Lakeside, and Chicago, Illinois. ⁓ So, yes, and it’s incredible because you’ve got the surgeon, and you’ve got the medical oncologist, and you’ve got the radiation oncologist, you’ve got researchers.
@TheOncoPT – Elise (10:43)
Mm-hmm. Mm-hmm.
That is insane.
Scott Capozza (11:03)
And it is international. So you’ve got people flying in from Japan and from Chile and from Spain, all presenting their most current research in oncology care. And so it can be a little overwhelming the first time. Because just think about how overwhelming CSM can be sometimes, especially as a first time attendee. So take that and triple the size of that.
@TheOncoPT – Elise (11:20)
Yeah, I can imagine.
my gosh, yes!
Scott Capozza (11:31)
And I always make the joke too, Elise, that we always have fun in the exhibit hall, right? We go and everybody gets their free Theracane and everybody runs on the new Zero G treadmill, that sort of thing. ⁓ Their exhibit hall is like our exhibit hall, ⁓ all jacked up on Mountain Dew because for better or worse, you’ve got…
@TheOncoPT – Elise (11:40)
Yup. Yup.
Hahaha!
Scott Capozza (12:01)
there. And so you’ve got these huge stations and they’ve got espresso bars and they’ve got smoothie bars and I was actually sent on a mission by my wife to go to the La Roche-Poussey table to go get free samples. So yes.
@TheOncoPT – Elise (12:02)
Yeah.
Yes, absolutely,
absolutely.
Okay, so it sounds like if nothing else, the exhibit hall is definitely a first stop for me when I go to ASCO. So American Society of Clinical Oncology, they have their annual conference, which was held this past, so technically not last weekend, but the weekend before. So I think we said like around May 30th, June 1st, and it’s quite a long conference is what you were telling me, right?
Scott Capozza (12:31)
absolutely.
Yeah, people usually start showing up on Thursday and they have some, know, kind of like almost like how we have like pre-cons at CSM. So ⁓ people a lot of times show up for that. And then, ⁓ you know, our good friend and the OG of oncology, have Nicole Stout. I know she presented the Friday on an ASCO this year. ⁓ And so, and it goes actually through Tuesday. I presented on
@TheOncoPT – Elise (12:54)
Mm-hmm.
Yeah, yeah.
Scott Capozza (13:21)
Monday morning of ASCO and they were still some breakout sessions on Tuesday. So it’s a good five, six day commitment if you’re going to go for the whole thing.
@TheOncoPT – Elise (13:30)
So intense.
That is so intense. But I mean, also with 44,000 people attending and I mean, countless, countless presenters. I feel like you would be hard pressed to fit that content into the, like the, you know, weekend conference that CSM kind of is. So that’s, that’s crazy. And it’s, it’s an annual conference, right? It happens every year.
Scott Capozza (13:55)
Yeah, just like for us how CSM is usually middle February ⁓ ASCO, the annual meeting is always, it’s usually the weekend after Memorial Day, ⁓ which is great in Chicago because it’s just starting to warm up, but it’s not muggy yet. ⁓ So, yeah, so this was my third time going to ASCO and I’ve been pretty lucky. Every time I’ve gone, ⁓ it’s been nice weather there. But just like how
@TheOncoPT – Elise (14:06)
Mm-hmm.
Yeah.
Scott Capozza (14:25)
we do also for through APTA that some of the sections have their own ⁓ sessions or conferences, right? ⁓ APTA ⁓ neurology does their own conference ⁓ later on in the year. ASCO does the same thing. So they actually do have a very specific ASCO GI symposium that they run every January, which I believe is in San Francisco. So, but just like
@TheOncoPT – Elise (14:51)
Mm-hmm.
Scott Capozza (14:54)
Yeah, so ASCO annual meeting, the one in Chicago at the McCormick Center is analogous to our CSM.
@TheOncoPT – Elise (15:01)
Now, do you go to this conference just for kicks and giggles or like somebody’s wondering in the audience right now, but you’re a PT Scott. Why are you going to the clinical oncology annual conference? Like talk to me about that.
Scott Capozza (15:17)
Well, so, me personally, I’ve been very fortunate that each time that I’ve gone, I’ve presented or I’ve spoken, and ironically enough, two out of the three times I’ve worn my survivor hat there. In 2017, 2018, I went and I spoke as a survivor through the Ask O Voices program where
That is, there’s no slides and it’s really just ⁓ an opportunity for people to kind of talk about the human side of oncology care. when I did that, when I did Ask Go Voices, there were five of us. They each gave us maybe 12 minutes on the stage, no slides. I was actually the only survivor. Everybody else were providers and they were telling very humanistic stories.
about their practices and that sort of thing. So that is always a highlight. A lot of people like to go to that because again, that’s the kind of the human side of oncology care. ⁓ Three years ago, I was fortunate enough to go, ⁓ the breast center that I work with, the providers that I work with, we had put together a poster. It was actually in reference to ⁓ referral patterns for women with lymphedema.
@TheOncoPT – Elise (16:22)
Mm-hmm.
Yeah.
Scott Capozza (16:44)
And so I presented the poster there. And then this past year, ASCO 2025, again, I went back as a survivor. ASCO is really putting, making a push to have more patient advocates involved. And this is actually a funny story. So last fall, I get this random email from ASCO and it…
@TheOncoPT – Elise (16:44)
Mm-hmm.
Nice.
Yeah. ⁓
Scott Capozza (17:12)
you know, it looks pretty official and it says, congratulations, you’re gonna be a speaker on this panel. I mean, at first I thought it was spam because I didn’t apply for anything. I mean, I literally put it through our IT department and said, I don’t wanna click anything because I’m afraid somebody’s phishing me here. It was a phishing scam. And so, the IT department ran it through, they’re like, no, no, this is legit. And I said, okay, fine. And no, and it gets even better at least, it gets even better.
@TheOncoPT – Elise (17:19)
No ⁓
Please check.
Scott Capozza (17:43)
Because, so I click on it and it’s like, you know, and there’s four presenters, there’s three oncologists, and there’s me, and it has me as Scott Capo as a patient advocate. Okay, great. They want to hear the patient voice. Awesome. The patient voice needs to be elevated at all of these conferences. And that’s a whole nother conversation that you and I can have about making sure that we elevate the patient voice at our own conferences. But anyway.
@TheOncoPT – Elise (17:49)
Mm-hmm.
Mm-hmm.
Right. Right.
Mm-hmm.
Right, right.
Scott Capozza (18:12)
So I go and I’m like, okay, fine, go into the speaker center. So do my conflict of interest forums and the whole thing. And I look and the panel was about oncologic care for patients with kidney cancer.
@TheOncoPT – Elise (18:30)
Alright, okay, hmm? Yeah, yeah!
Scott Capozza (18:31)
And I thought, that’s not the cancer I had.
So I emailed the moderator and I said, so just so you know, I’m psyched that you’ve got a patient advocate here and that you reached out to me. I’m honored, but just so you know, that’s not the cancer I had. And he wrote back and he’s like, no, no, we just, need the patient voice. Like we need to know like the decision aspect of it. Like when you sit down, when the patient sits in the room, the medical oncologist or the surgeon and they say,
@TheOncoPT – Elise (19:03)
Mm-hmm.
Scott Capozza (19:06)
This is what we’re going to do. What’s going through the patient’s head? We want you to do it that way. So anyway, so that’s that was for me this year. But to answer go back to answer your question about why should PTs go to ASCO and potentially other conferences that are not CSM.
@TheOncoPT – Elise (19:10)
huh. Gotcha.
Mm-hmm.
Scott Capozza (19:26)
We’re working with these surgeons. We’re working with these medical oncologists. We’re working with these radiation oncologists.
They need to know that we’re part of the team. So first and foremost, we need to be present. Second of all, we need to find ways to get even more involved and to present at these conferences so that again, these providers know how crucial rehab is to their patients. And so we’ve had this conversation offline. I hate silos.
@TheOncoPT – Elise (19:40)
Mm-hmm.
Mm-hmm.
Scott Capozza (20:06)
I hate silos.
@TheOncoPT – Elise (20:06)
Yeah.
Scott Capozza (20:06)
It does not do anything for patient care. The patient feels disjointed trying to go from one person to the next. And so if we can seamlessly work together. So that’s why it’s so important that. And then the other thing, the other aspect of that is we as onco-PT’s, we need to know what’s going on. We need to know what these new drugs are.
@TheOncoPT – Elise (20:13)
Yep. Yep.
Exactly. Exactly.
Scott Capozza (20:35)
We need to know what these new clinical trials are. We need to know how they’re changing these protocols. There was one thing that they presented there, ⁓ which I thought was interesting. ⁓ There was a study that came out about potentially omitting Carboplatin from neoadjuvant therapy for women who are HER2 positive for early stage breast cancer. Great. Awesome. That’s great.
@TheOncoPT – Elise (21:00)
Mm-hmm.
Scott Capozza (21:03)
We definitely don’t want, know, if they can take Carboplatin out of it and we still get overall survival rates, that’s fantastic. Another study that came out this year, it was the Destiny Breast 09 study, was again, they’re looking at the tracking overall survival and progression-free survival in patients. And so they found that Chinusabab, Deroxacam, which is the TDXD,
@TheOncoPT – Elise (21:08)
Right.
Mm-hmm.
Scott Capozza (21:33)
plus Produzumab, ⁓ it gave patients ⁓ an extra 13, 14 months of survival for patients who have metastatic breast cancer, which is awesome, right? We’re giving these patients an extra year plus of life. How’s their quality of life?
@TheOncoPT – Elise (21:50)
incredible.
Mm-hmm.
Yeah, exactly. Exactly.
Scott Capozza (22:01)
So if these patients are going to be able to switch to a different protocol and they’re going to live another year or so, that’s amazing. That gets them to their kids’ high school graduation. That gets them to their kids’ wedding or whatever it might be. But they got to be strong. They got to be able to get to their wedding. They got to be able to walk their daughter down the aisle. That’s what we do. So we have to be cognizant of these
@TheOncoPT – Elise (22:07)
Mm-hmm.
Right.
Exactly.
Mm-hmm.
Scott Capozza (22:29)
protocol changes, new drugs, new clinical trials, because guess what? Our patients are going to look this up. And so they may very well ask us, what do you know about Destiny Breast 09? We got to know.
@TheOncoPT – Elise (22:38)
Yep.
Mm-hmm.
Yeah. And it’s, this is a really good point you bring up as there was a lot of conversation and I’m getting my information. Like there are different oncologists and other healthcare professionals on social media who were sharing their conference takeaways and whatnot, which was really exciting. And I don’t know if I was just, if I’ve curated my algorithm to really get this, or if more people were just on
the ball of sharing these insights at the conference. It could be both, who knows? But there was much more conversation happening that I could watch real time as far as changing the norm or the expectation when it comes to overall survival that patients can expect when it comes to different protocols and whatnot, which is really exciting. Ed, the big but, the big but that Scott brings up here is,
overall survival increases, what about that quality of life? What about their functional mobility, their independence as they are living now longer, whatever that looks like for them. And who better to take that information and implement it into practice, not just with our patients, but also in conversation with our oncology teammates, right? To say, okay, I know that this might be happening, or if this is happening in your practice,
This is a consideration. This is how I can help fill this gap for your patients. How exciting. What an exciting time to be in oncology physical therapy. Like, ugh!
Scott Capozza (24:20)
Yes, yes.
there’s the, we’re gonna talk about the Holy Grail in a second, but there’s one other breast specific one I wanna make sure, again, because we’ve gotta be aware that the oncologists follow, they have their own guidelines, just like we have Edge Task Force guidelines for us as oncopTs. They have their own guidelines. so there is something, they’re gonna be trying to move. There’s new evidence.
@TheOncoPT – Elise (24:26)
Mm-hmm. my god.
Mm-hmm.
Mm-hmm.
Scott Capozza (24:50)
that shows that in select patients with early stage breast cancer, they’re now talking about getting rid of sentinel lymph node biopsy.
@TheOncoPT – Elise (24:55)
Mm-hmm.
what?
Scott Capozza (25:02)
Right? talk about,
again, quality of life. If these patients don’t need to have, never mind an axillary lymph node dissection, but if they don’t have to have a sentinel node, again, very specific population within the breast population. But can you imagine, that again, that’s going to significantly change the landscape of how we see these patients because, okay, well, you know, if they don’t have the lymph node dissection, you know, what does that do for their
@TheOncoPT – Elise (25:10)
Right?
Totally.
Right.
Scott Capozza (25:32)
It helps lower the risk of lymphedema. ⁓ But again, patients are also very savvy now, and so they’re going to look this up. And so they’re going to come to us. They’re going to come and they’re going to have these questions ready to go. And so we have to be prepared. We have to do a little bit of homework ahead of time. And again, think outside of our PT box so that we can speak oncology.
@TheOncoPT – Elise (25:34)
Exactly. Exactly.
Mm-hmm. Mm-hmm.
Mm-hmm.
Right, right, right. ⁓ We’ve alluded to the Holy Grail a few times now. I think it’s time to bring out the big guns, Scott, because there was, again, there were lots of things coming out of ASCO this year that were just really, really exciting. But this one…
Scott Capozza (26:02)
across the board.
@TheOncoPT – Elise (26:24)
I don’t know that I even have words to convey like how big of a deal this next piece of like literature and whatnot that came out. So let’s just get into it, Scott. Tell us what is this Holy Grail that we keep talking about.
Scott Capozza (26:40)
So it’s the CHALLENGE clinical trial, which is based out of Canada. ⁓ It involved ⁓ patients both from and researchers from Canada and Australia. And it was an exercise trial for patients with stage 2 and stage 3 colorectal cancer. ⁓ And they ended up enrolling almost 900 people over the course of… ⁓ It was from…
@TheOncoPT – Elise (26:46)
Mm-hmm.
Scott Capozza (27:09)
2009 to 2023. So for like 15 years. So it was a long time and they tracked these patients for years after the intervention. a significant study, a lot of time and effort and resources went into this trial. incredible, incredible work. And so what they did was they had their
@TheOncoPT – Elise (27:13)
Mm-hmm. Yeah. my God.
Scott Capozza (27:39)
⁓ Their intervention was patients were either randomized to an exercise group or a, like what they call like a health consultant group. So the control, the health consultant group basically got the piece of paper to say, go exercise.
@TheOncoPT – Elise (27:44)
Mm-hmm. Okay.
Yeah.
Mm-hmm. Exercise good. Go do on your own. Good luck.
Scott Capozza (28:04)
the intervention group met with ⁓ what they called a physical activity consultant. You can very easily submit in their physical therapist. ⁓ And they met with the physical activity consultant twice a month for six months. And then they spaced it out even more over the course of three years to still meet once a month. So they still had that touch point. They had that touch point to
@TheOncoPT – Elise (28:13)
Mm-hmm. Mm-hmm.
Mm-hmm.
Scott Capozza (28:34)
you know, see how they’re doing, change anything if they needed to, ⁓ you know, it helped with adherence, it helped with, you know, being able to follow up with these patients. The patients didn’t feel like they got lost through this whole thing. So, incredible. So, they looked at the numbers and so what they found was that the group that was in the structured exercise program, again, structured.
@TheOncoPT – Elise (28:46)
Mm-hmm.
Mm-hmm.
Scott Capozza (29:01)
some
level of supervision, somebody is watching them and motivating them and modifying these exercises. They found these patients had a 28 % ⁓ lower risk of recurrent cancer or new cancers, right? So over a quarter of these patients, they lower their risk of recurrence.
@TheOncoPT – Elise (29:04)
Right.
incredible.
Scott Capozza (29:25)
by exercising, by moving. And it gets better. If you can believe that, like that’s incredible, right? Right there, they’ve got the evidence. It gets even better. they track, again, they track these patients and after eight years, they found that these patients who were in this trial, it lowered their risk of death by 37%. One third.
@TheOncoPT – Elise (29:30)
Yeah. Yeah. Right.
Yeah. Yeah.
Scott Capozza (29:54)
it will reduce their risk of death from their disease.
and to put the cherry on top of this whole thing, these outcomes, right, 28 % lower risk of recurrent cancer, 37 % lower risk of death, was better than some chemotherapy regimens.
@TheOncoPT – Elise (30:07)
Mm-hmm.
That was my favorite part of opening the trash fire that is social media and seeing that graphic. And I don’t know if it was Dr. Liz O’Riordan or Dr. Teplinsky that I saw it from on social media, but they posted that chart that compared this. So in this trial exercise against
Again, it was different chemotherapy regimens that these patients oftentimes undergo and exercise was like exercise was better than some of that, which is insane to think about. And again, what a better way. Again, we know we’ve known this for a while here on the Onco PT and in cancer rehab. Exercise is really good for people.
There’s numerous benefits, countless benefits that are supported in the literature time and time again. But to see such a resounding level of support in the evidence for what exercise can do for a person’s survival and recurrence.
I don’t know how to communicate how groundbreaking this is. And maybe even groundbreaking is not the word that I’m looking for. This is truly a moment where we are at, I think a tipping point in oncology rehab to have such substantial, and we’ve had substantial information previously, but for this level of evidence to be recognized on a national and international level,
at ASCO of just how good exercise is for this patient population and more as we can surmise, this is a point at which we as oncology rehab professionals can take this and run with it or we can watch us watch it pass us by. I believe this firmly in my soul Scott. Now that’s me. ⁓ Tell me your thoughts on this, right? Like you’re, ⁓
getting this information as it’s coming to you live, like what are you thinking as you’re listening and hearing this?
Scott Capozza (32:33)
Well first of all, validates everything that we do. now it’s, and by the way, know, this, when they presented this, like, they got a standing ovation. So that just shows you that the doctors appreciate this now. They’re like, wow, like, this really is, this is seismic as far as to be able to, and that’s, I mean, that’s the strength of this study.
@TheOncoPT – Elise (32:36)
Yeah, yeah.
Mm-hmm.
Scott Capozza (33:01)
almost 900 participants over 15 years. This was not some little pilot study somewhere. And obviously we need pilot study because this was not a pilot study with 20 people. This was 900 people, 15 years. Yeah. So this was, they have put a lot of effort into this. yeah, so this was presented on the Sunday of ASCO. Sunday night.
@TheOncoPT – Elise (33:09)
Of of course.
in nearly 15 years. Yeah, yeah.
Mm-hmm.
Scott Capozza (33:30)
I was able to meet with some of my providers that I work with and I went right to one of my friends who’s a medical oncologist in GI and I was like, so this is the evidence we need so we can finally get our gym, right?
@TheOncoPT – Elise (33:43)
Right? Right?
Scott Capozza (33:45)
Yeah, and he was all jacked up. He’s like, yeah, absolutely, because he and I have been advocating for a gym at his clinic for years now. So this is it. This is the evidence. this is, I, of course, you know, everything gets implemented, you know, at different rates, at different places. But this does lay the groundwork for what we do. And, you know,
@TheOncoPT – Elise (33:54)
Mm-hmm. Mm-hmm.
Mm-hmm.
Scott Capozza (34:13)
And this is movement, this is exercise, this is rehab. And then if you, I’m sure, if you pull in nutrition, are we talking about 50 % reduction in risk of dying from your cancer? Like, that’s gonna, I’m sure that’s coming next and we’re gonna have that evidence to say, okay, yes, rehab and exercise combined with nutrition, sensible nutrition.
@TheOncoPT – Elise (34:22)
my gosh. For real.
Right.
Scott Capozza (34:43)
is going to be more efficient at preventing recurrence of cancer than drugs.
@TheOncoPT – Elise (34:46)
Right.
Right. You know, and.
I honestly, I have so many thoughts, but I really want to capitalize on number one. When Scott said seismic, I don’t know if it came through because I can obviously hear it. There was a huge thunder clap here in Texas because we’re in the middle of a thunderstorm. So I thought that was very fitting. The heavens agree. This is monumental, the level of information. And I want to kind of camp on something for a little bit, I agree with you that
things get implemented at their own rates in their own communities. I get that. However,
These findings were just published, okay? They’re new, they’re exciting. There is excitement behind these and there is momentum behind this. And you, the person with your earbuds in listening to us right now, this is an opportunity where if you have been working in your community and you feel like I am just not getting where I wanna be in a timely fashion or as fast as I want to.
Maybe this is that pivotal next step of how we leverage those relationships and the communication and the, you know, the networking that you’re building in your own community to make these things happen. Because again, it is not just physical therapy shouting into the void saying how important exercise is. this is so much bigger than.
any one of us than all of us together. Like this is changing people’s lives. It is saving people’s lives. It is giving people’s lives back to them. And we have a real opportunity to step up to the plate and do something with this now. Because the last thing that I want is for we have all this excitement and all this amazingness coming out from this research that was published only for it to kind of fizzle out and for it to go nowhere. And if you’re waiting for
you know, some big organization to come through and say, okay, everybody, here’s how we’re going to implement it. That’s not how it works. It starts at the ground level in each individual community to help make this happen, to foster this becoming standard of care. It’s not going to come, like I do think there’ll be stuff that comes top down, but I also think a lot of this is going to be bottom up.
when it comes to the implementation of this, especially if you’re in a community that you don’t have a major academic institution where rehab is embedded and all the things that we know and we want and we love for our patients and ourselves to have. That may not be your clinical reality. It’s on you, the listener. It’s on me, it’s on Scott. It’s on everybody to actually make this happen in our own communities. So we need to harness.
the excitement and the momentum and the motivation that we as an oncologic community have in the aftermath of ASCO 2025.
Scott Capozza (38:00)
Yes, and I would 100 % to everything you said. And what I would hope is that by listening, we can empower everybody who’s listening and empower our colleagues, especially the ones who are in smaller communities that are not necessarily near large academic institutions, to send that email. Send that email to the local oncologist and you tag this study.
@TheOncoPT – Elise (38:17)
Mm-hmm. Mm-hmm.
Scott Capozza (38:30)
Because when other oncologists are putting it out on their LinkedIn and on their Instagram and everything, you know that it has caught the eye of so many oncologists. So that’s great. That’s incredible. But the change does start with us. And to start that conversation and to include this study and say, now here’s the evidence that was… And that’s again…
@TheOncoPT – Elise (38:46)
Mm-hmm.
Scott Capozza (38:58)
That’s speaking oncology. You’re speaking their language. When you say, this was presented at ASCO 2025, that’s going to get their attention versus this was presented at APTACSM. They don’t know what that is, but they know what ASCO is.
@TheOncoPT – Elise (39:00)
Mm-hmm.
Mm-hmm. Right, right.
Yeah, yeah. And again, 44,000 attendees. Listen, APTACSM is no like little party, okay? It’s big. This is bigger. And again, I think the choice, and I truthfully don’t know who all was on that study. I’ve looked up some of the authors, but the fact that this was presented at a medical conference, I think is only better for us in the long run, because again,
more eyes on this study, more eyes in places of referrals, not that we should rely on referrals, y’all, okay, but more eyes who are potentially in positions where they can start saying, okay, we’re gonna implement this. We need to make those connections happen, but that needs to be met, like I said, by that bottom up approach. again, this is not to say like PT is beneath MDs. That’s not what I’m saying at all.
But again, the grassroots movement needs to meet the, you know, coming down from the, ⁓ you know, leadership entities and whatnot, the professional organizations like ASCO.
Scott Capozza (40:22)
I agree. And I think the other thing to consider too, again, you know, for our colleagues who are in maybe smaller communities is, you know, and I think we’ve talked about this before on previous podcasts is that, you know, if you can tag the patient voice, actually, that’s what we led with today, the patient voice. If you get that one patient who said, I went to Elise because I was super deconditioned after 12 rounds of full Fox chemotherapy because of
@TheOncoPT – Elise (40:40)
Mm-hmm. Mm-hmm.
Mm-hmm.
Scott Capozza (40:52)
my colorectal cancer, she got me moving and now not only is it easier for me to go up and down the stairs to do laundry, now again I can walk my daughter down the aisle for her wedding in three months.
@TheOncoPT – Elise (41:07)
Mm-hmm. Mm-hmm.
Scott Capozza (41:09)
That gets people’s attention and then you attach this study and it’s like, there’s the evidence behind it. Elisa is not just pulling this out of thin air. This is real.
@TheOncoPT – Elise (41:15)
Yeah, right. Exactly.
Oh my gosh. Again, we love a good anecdote, but 900, 900 participants in this.
Scott Capozza (41:31)
15 years, over 15 years, yes.
@TheOncoPT – Elise (41:36)
⁓ my God. Okay. There was some really big stuff that came out of ASCO and obviously like this, like we’ve said, this is like the Holy grail when it comes to cancer rehab for us. Going back now, like you have left ASCO, you’re going back into your own community. You know, you’ve been back for like a week now.
What are some of the big takeaways or the things that you’re going to now be implementing in your own practice, in your own community, with your own patients?
Scott Capozza (42:08)
So I left ASCO on Monday, ⁓ and on Tuesday, an email chain has started to say, we need to get all the players in the room to start thinking about how we’re going to implement this, that GI doc I was just telling you about before. So because he’s a big proponent of exercise. So yes, so it started, it started within 24 hours, which is great.
@TheOncoPT – Elise (42:25)
my God.
Yes!
Scott Capozza (42:37)
We are, we are going to meet in a couple of weeks and just start talking about how can we, you know, again, I don’t know that we’re going to be able to get $50,000 worth of gym equipment right off the bat, but even just figuring out how to get those patients, you know, to rehab a little bit faster, you know, some sort of automatic referral, ⁓ they’re anything, if they’re going to get oxaloplatin as part of their chemotherapy regimen, because we got to make sure that we
@TheOncoPT – Elise (42:55)
Absolutely. Absolutely.
Scott Capozza (43:06)
take care of the or address the neuropathy aspect of things. Okay, great. That’s what you that’s what EMR is supposed to help you with. So that’s one thing right there. The other thing that the other breakout that I actually went to, it was actually a working group for for the adolescent young adults for an AYA population. And I really was in the room of all the Hoosiers like the founder of Elephants and Tea and ⁓
@TheOncoPT – Elise (43:09)
Right. Right.
Mm-hmm. Mm-hmm.
Yeah.
Scott Capozza (43:35)
representatives from Stupid Cancer, ⁓ Dr. Michael Roth from MD Anderson and John Salzman from WIC Forest. And I’m looking around and say, boy, I really am here with all the big wigs. ⁓ But to come up with, again, to your point, Elise, about how do you get ASCO guidelines and to get them into the community?
@TheOncoPT – Elise (43:37)
Yeah!
Mm-hmm.
Scott Capozza (44:03)
We’re developing a working group to figure out again, especially for our AYAs, they may travel to a large medical institution to get their treatment, but that’s not necessarily where they’re going to get their rehab from. They’re going to get their rehab locally, which may be 90 minutes, three hours away from where they were. So we’re trying to talk about how do you, you know, do we come up with a logo that’s got a QR code that then like, it’s easy to just
@TheOncoPT – Elise (44:14)
Mm-hmm. Mm-hmm.
Bingo. Bingo.
Mm-hmm.
Scott Capozza (44:32)
get that out to community-based oncologists. The oncologists don’t have to have all the answers, but if ASCO can put together like a resource hub, and then the AYA scans that with their phone, and it directs them there. So it directs them to LFSNT, and it directs them to stupid cancer, and Livestrong Fertility, and all those resources, then great. So ⁓ that email.
@TheOncoPT – Elise (44:49)
Mm-hmm.
Mm-hmm.
Yeah.
Scott Capozza (45:01)
is going around right now also. ⁓ that’s really exciting. So I think for us as OncoPT, again, to take some time and yes, there’s great research that comes out of our own journals, but if you can peruse ASCO, ⁓ the Journal of Clinical Oncology, again, there’s not a lot of rehab that gets
published in the Journal of Clinical Oncology, but least to be cognizant of these new protocols, new drugs, what are they taking out of protocols. So again, when you have that conversation with the oncologist, you you feel comfortable and competent to have that conversation.
@TheOncoPT – Elise (45:33)
Mm-hmm. Right.
Mm-hmm. Mm-hmm.
I, and this is a slight aside, but one of the things that I’ve really gotten a lot of benefit out of ⁓ over the past, probably like year and a half is when I really started this, but I use the NCCN guidelines a lot when it comes to like writing oncology specialist bootcamp and whatnot. But they do a really nice, I don’t know, like weekly or monthly email debrief where they kind of compile, like what are some updates? And some of those are, you know, the NCCN guidelines updates.
but also different articles. I really, and this is to Scott’s point, I like them because they talk about, again, what’s kind of happening on the medical oncology side. What are they finding when it comes to like, hey, this treatment is working for this. And you know, here’s the numbers behind that and whatever. Because it’s nice to know what’s happening on the medical oncology side, the clinical oncology side of things. So that when my patient comes to me and says, I’m on this medication, I can say, ⁓
I know what that is. And more importantly, I know what kind of side effects to expect and what to do about that. And the same thing goes here for ASCO. And you know, I’m sure ASCO has like an email list that you can join. And I know we already have probably hundreds of emails in your inbox, but even just to do a quick glance on what’s happening, what is relevant to me and my practice. I love a good abstract scan.
And then I can, you know, do what I will with that article. And maybe I, you know, like bookmark it and I save it for later, or maybe I just glance over it and say, okay, that was good. But something like Scott has said so many times in this interview of being aware of what is happening so that when your patient comes in and is asking questions about this, you can ensure that you’re informed and you can then help them with whatever it is that they’re coming in dealing with and specifically seeking your help for. So.
This is so exciting. ⁓ my God.
Scott Capozza (47:53)
And
so maybe one thing just to ⁓ interject in here too is that just like we have the app for when we’re at CSM and you can search for presenters, can search for themes, sort of thing. That’s the same thing. And so it was easy for me to just put in Young Adult Survivor. And it told me which posters, which breakout sessions, that sort of thing. You can put in exercise.
@TheOncoPT – Elise (47:58)
Mm-hmm. Mm-hmm.
Mm-hmm. Mm-hmm.
Yeah. Yeah.
Love that.
Mm-hmm.
Scott Capozza (48:21)
put in rehab. so, so in the future, moving forward, I highly recommend if you can go once, if you can go to ASCO and just see it, feel it, experience it. Like I said, it’s it’s CSM all jacked up on Mountain Dew. But it’s great. And there’s just the buzz, the energy, like everybody’s talking and you know, again, you’re also
@TheOncoPT – Elise (48:41)
my gosh.
Scott Capozza (48:51)
seeing researchers and doctors from all over the world. But you can search for rehab, can search for exercise, you can search for lymphedema, you can search for whatever you want to search for in the app to find out which breakout sessions to go to, which posters that you want to go visit with, and take that information and bring it back home to your patients.
@TheOncoPT – Elise (49:07)
Mm-hmm. Mm-hmm.
Scott, I’m really excited to see what comes out of that breakout session that you’re a part of with AOIA. Because obviously I know that that’s a very, very special place in your heart, very underserved patient population. We’ve talked about this many a time on the podcast. We haven’t really talked about your presentation yet. Can we talk about your presentation at ASCO and how did that go?
Scott Capozza (49:42)
So it was really nice. So there was the four of us and the three oncologists were talking about the latest research in treating
kidney cancer and ⁓ imaging, if a patient ⁓ progresses, ⁓ what’s the protocols for screening? And they had a of polling questions, so they were putting it out to the audience. In a situation like this, do ⁓ you do PEMBRO in this instance, or do you not do PEMBRO in this instance? So it was really kind of interesting to see that, but then they would turn to me and they’d say, so
@TheOncoPT – Elise (50:20)
That’s cool.
Scott Capozza (50:22)
what’s going through the patient’s head. And there was one point where they talked about surveillance. And they said, yeah, well, at this point, we would probably move the patient to surveillance.
And my two cents was, surveillance could be a scary word.
@TheOncoPT – Elise (50:46)
Yeah, yeah.
Scott Capozza (50:48)
Surveillance might be interpreted by the patient as, ⁓ well now what? know, very similar to survivorship in the sense of, for better or worse, you’re at the cancer center and you’re getting treated and you’re kind of in that safe little bubble because you’ve got nurses taking care of you and they’re checking your blood levels and all of that. So you’re at least got somebody keeping their eyes on you.
@TheOncoPT – Elise (51:10)
Right.
Scott Capozza (51:15)
And then if they say, okay, well, surveillance, we say, well, what if? What if something happens? if, you know, what if now between now and six months from now, the cancer starts to grow again? You know, are my counts okay? Like all of that. And so that was to that particular ⁓ case, I said, you have to be careful. You can’t just automatically assume that surveillance that the patient is going to start jumping up and down out of their chair.
@TheOncoPT – Elise (51:32)
Mm-hmm.
Right, Yeah. ⁓
Scott Capozza (51:45)
they might be a little scared.
so surveillance might have to come with a caveat of if you need anything or we’ll have the nurse check on you, call you in a month or something like that, ⁓ that sort of thing. You can’t just blanket statement say, you’re on surveillance, hooray, see you in six months.
@TheOncoPT – Elise (51:58)
Mm-hmm.
Right,
right, right. That drop off, that’s what my patients have likened it to. It’s like a drop off a cliff of like, I’m falling and I don’t know if I’m gonna get caught at the bottom or if I have like a safety rope or something. It’s just kind of a big void that they feel like they’re metaphorically going into. Yeah.
Scott Capozza (52:32)
Yeah, that was so it great. So again, it was nice that they’re integrating more patient advocates at this conference to have the patient voice heard. And, you know, so my hope is that, ⁓ you know, as ASCO continues, and I would therefore also say for us at CSM, that we think about how can we include
that patient voice because the one thing that carries the most weight at the end of the day is how’s our patient doing? And we don’t know until we hear from them.
@TheOncoPT – Elise (53:02)
Mm-hmm.
Mm-hmm.
Yep. Absolutely. For the clinician who’s listening right now and who’s considering, maybe I should go to ASCO. Maybe I should go to ASCO next year. What would you tell them?
Scott Capozza (53:29)
I’d say bring plenty of snacks, just like you do, just like when you do CSM, bring good walking shoes, like all the fundamental stuff that you do when you go to a big conference like that. But I think also because it can be overwhelming, go in with a little bit of a, not a hard and fast plan, but at least an outline. Maybe an outline.
@TheOncoPT – Elise (53:32)
Love it. Love it.
Mm-hmm.
Mm-hmm.
Totally, totally.
Scott Capozza (53:58)
is the best way to describe it. Again, go through the app ahead of time, do your search, see what you want to view or what posters you want to go to, that sort of thing. But also walk around and listen and maybe you find something that, like for me, I’m not an lymphedema therapist, but if there’s something that’s new, like I was referring to before, this new study where they’re talking about
@TheOncoPT – Elise (54:00)
Mm-hmm.
Mm-hmm.
Scott Capozza (54:26)
potentially not doing sentinel lymphobioty in certain early stage breast cancer. Maybe I need to go into that one because again, I’m going to get those patients and so I need to be cognizant of that or I might say, wow, I’m not seeing a lot of multiple myeloma patients. So maybe I need to go to one of those breakouts. So that way when I go back home,
@TheOncoPT – Elise (54:34)
Mm-hmm. Mm-hmm. Right. Right.
Mm-hmm.
Scott Capozza (54:56)
I can reach out to those docs and say, I was just at ASCO. I went to this breakout about multiple myeloma, and they presented this new drug, which all sounded well and good, but it causes neuropathy. You don’t want your patients falling in the middle of treatment, do you? Send them to me.
@TheOncoPT – Elise (55:11)
Mm-hmm. Right.
Right.
Scott Capozza (55:17)
So
an outline is good to allow also some flexibility. And I would also then also say for anybody who does decide to go to ASCO, give yourself a little bit of time to explore Chicago. It’s a great city. you should do a little bit of tourism while you’re there. ⁓ But yeah, it’s great. the other thing too about ASCO, if you stay at
@TheOncoPT – Elise (55:20)
Mm-hmm.
great city.
Scott Capozza (55:46)
If you stay at one of the many hotels on the magnificent mile there ⁓ that are all kind of affiliated with ASCO, they have shuttles. Yeah. ⁓ it’s great. I never, so I never had to Uber over to the McCormick Center because McCormick Center is south of the city. ⁓ So, you know, when you check into your hotel, you just ask them, you know, what street corner does the
@TheOncoPT – Elise (55:58)
⁓ wonderful.
Okay, okay.
Scott Capozza (56:16)
does a shuttle come, what number of shuttle is there. So I had shuttle number five and it was right outside my hotel and they run like every 15 minutes because you gotta get 44,000 people there. So that was nice.
@TheOncoPT – Elise (56:24)
I love that.
Okay, I would like to formally petition to have CSM in Chicago so we can have those shuttles. Listen, I love a good public transportation, like trains and whatnot, but shuttles? Next level. I need that. Yes, please.
Scott Capozza (56:46)
Yes. Yes.
Yeah, like I said, it was great.
@TheOncoPT – Elise (56:55)
Very, very cool. So this was your third time going to ASCO. Do you think your experience has changed at all over the years of going first pre-pandemic as a patient advocate, and then as you’ve gotten, you’ve become a specialist, a board certified specialist in oncologic physical therapy? You’re now involved in a lot more.
speaking and teaching opportunities. Has that shifted any of your experience at ASCO over the years?
Scott Capozza (57:28)
Yeah, this year I did not feel as overwhelmed again because I’ve gone a couple of times and again, you know, working hard to create these relationships with other people and with doctors and that sort of thing. You know, it was nice to bump into a few people. I did have a fanboy moment. I did bump into Dr. Liz O’Riordan and I was like, all I said was
@TheOncoPT – Elise (57:53)
Ugh, who we love.
Scott Capozza (57:57)
It’s great to meet you and thank you for all you do. Like she doesn’t know me from anybody else, but so yeah, so you see, you know, so you see people like that, that we all follow, right? On social media or whatever. But, but again, we, we do belong at that table. So don’t be intimidated to be there because again, at the end of the day, who’s going to get these patients moving again?
@TheOncoPT – Elise (58:09)
Mm-hmm. Yeah.
Scott Capozza (58:27)
And who’s going to get these patients stronger? And who’s going to get these patients to return to a good quality of life? It’s us.
@TheOncoPT – Elise (58:34)
Mm hmm.
Yes. Yes. ⁓ 100%. Scott, this has been a really wonderful conversation. Is there anything else you want to leave the listeners with about ASCO before we sign off for today?
Scott Capozza (58:50)
Again, I would just wrap up and say that in order for us as oncology physical therapists to treat the whole person, we have to work together with the other providers. Again, the doctors, the nurses, the social workers, the dieticians. So we all have to work together. And so I think the more that we can collaborate, the more that we can
@TheOncoPT – Elise (59:02)
Mm-hmm.
Scott Capozza (59:19)
kind of step out of our comfort zone sometimes and go to these other conferences. It’s enlightening and it is also energizing for us. So I think it also validates what we do as oncology physical therapists. And it also, again, at the end of the day, also gives us an opportunity to look at.
@TheOncoPT – Elise (59:37)
Mm-hmm.
Scott Capozza (59:45)
the opportunities for oncology physical therapy to treat these patients.
@TheOncoPT – Elise (59:47)
Hmm.
⁓ okay. That was it. That might be your soundbite for the episode. I love it. I will also link to the studies and the, you know, the information that we talked about in today’s episode. I will link those in the show notes, which you can find at the oncopt.com, ⁓ slash podcast. And if you go to the specific episode, that will also be there for you. ⁓ I know we talked about obviously the challenge trial.
There were others that are so worth your time in just diving into and exploring and seeing again, how is this relevant to me? How can I implement this in my own practice, in my own community, for my own patients? Really exciting stuff coming out of ASCO 2025. It’s going to be really wonderful to see what continues to come out, how it is implemented into practice, and how our colleagues across the country are using this information. So I’m very, very excited about this.
Scott, thank you so much for coming on the Onco PT podcast once again. Would you like listeners to connect with you or follow you somewhere so they can continue this conversation?
Scott Capozza (1:00:54)
Yeah, so I am at Scott Capoza at both ⁓ Instagram and LinkedIn and all the social media platforms. At least you’re free to share my email as well in your episode notes. yeah, will, if not now, then definitely in future CSMs, happy to connect.
@TheOncoPT – Elise (1:01:16)
Yay! Well, thank you so much, Scott. And until next time, this is Elise with the OncoPT. And remember, you are exactly the physical therapist that your patients with cancer need. So let’s get to work.